ABOUT HUGEL
New Hope, Better Life
History
COMMERCIALIZATION
-
2011
- 12
- Received IND approval for phase III clinical trial for pediatric cerebral palsy
- 10
- Received KFDA approval for Botulax® 50 units
- 09
-
Awarded as "Prime Minister Prize of Innovative Product Botulax"
on the Local Development Week in 2011
Received KFDA approval for Botulax® 200 units
- 07
- Received IND approval for phase III clinical trial for glabellar lines
- 06
- Initiation of approval process for international commercialization
-
2010
- 12
- Obtained first overseas marketing approval for botulinum toxin in Peru
- 03
- Received KFDA approval for botulium toxin(blepharospasm)
- 02
- Received EN ISO 13485 certification for medical equipment quality control system
-
2009
- 06
- Established Hugel Pharma, a marketing subsidiary
- 03
- Received KFDA approval for botulium toxin export
-
2008
- 11
- Certified as a venture company(Korean Venture Capital Association)
-
2007
- 09
- Received IND approval for phase III clinical trial for blepharospasm
-
2006
- 10
- Completed construction of KGMP plant in Techno Park, Chuncheon